VIMAB Group AB

As of June 30, 2026, VIMAB Group AB carries a market capitalization of 138.41M, placing it among publicly traded companies globally. Its enterprise value stands at 221.68M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

VIMAB Group AB's next confirmed earnings release is scheduled for December 2, 2026.

As of June 30, 2026, VIMAB Group AB has 47.56M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 0.31, and the price-to-book ratio stands at 27.80.

These figures are as of June 30, 2026. The EV/Sales ratio of 0.66 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 221.68M versus a market cap of 138.41M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, VIMAB Group AB maintains a current ratio of 0.61, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026. Return on assets (ROA) is negative at -35.95, reflecting losses generated across the asset base. The company generates approximately 1.72M in revenue per employee across its workforce of 197.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.04 indicates how many times VIMAB Group AB sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, VIMAB Group AB recorded an income tax benefit of -505,000.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -85.16M and -84.65M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, VIMAB Group AB's stock has declined approximately 56.67% over the past 52 weeks. The 50-day moving average sits at 3.75, while the 200-day moving average is 3.04.

Over the twelve months ended June 30, 2026, VIMAB Group AB generated 337.94M in revenue and converted that into -84.65M in net income, yielding earnings per share of -2.36. EBITDA reached -27.82M, while operating income came in at -72.99M.

As of June 30, 2026, VIMAB Group AB holds 20.03M in cash and equivalents against 103.31M in total debt, resulting in a net debt position of 74.69M. Total book value stands at 4.98M, with working capital of -83.10M providing operational flexibility.

VIMAB Group AB produced -37.71M in operating cash flow over the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, VIMAB Group AB posted a gross margin of 64.67, reflecting its pricing power and cost economics. The operating margin of -21.60 and net profit margin of -25.05 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -36.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -38.48, meaning VIMAB Group AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.